menu
FR | EN
Digital Healthcare Community
Certified Medical Tourism ProfessionalBest Medical Travel Agency 2015Best use of technology in Medical Travel 2017

Cancer-killing virus injected into human in new trial

07/06/2022

Cancer-killing virus injected into human in new trial

A virus that infects and kills cancer cells has been injected into a human patient for the first time as part of a new clinical trial.


The novel therapy, CF33-hNIS, also called Vaxinia, is what is known as a oncolytic virus i.e. one that deliberately targets cancel cells while avoiding healthy cells. It infiltrates the cancer cells and rapidly replicates, killing its host.


At low doses, the therapy has been shown to reduce the size of a broad range of cancers in animal and laboratory models. And according to Imugene Limited, a clinical cancer research company, it can also help prime peoples' immune systems against cancer.


For the phase one clinical trial, Vaxinia will be injected into people who have solid tumors and have received at least two types of prior treatment. The virus is either injected directly into the tumor itself or via the patient's vein. This phase of the trial is designed to judge Vaxinia's safety and tolerability in human patients.


"Our previous research demonstrated that oncolytic viruses can stimulate the immune system to respond to and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies," says City of Hope oncologist and principal investigator Daneng Li.


"We believe CF33-hNIS has the potential to improve outcomes for our patients."


*Image courtesy of PIRO4D from Pixabay

expand_less